TNF and plasma cell myeloma: Although proven successful in targeting multiple myeloma the exact mechanism of action of thalidomide is yet to be elucidated although anti-inflammatory effects have been attributed to inhibition of TNF-α production by monocytes and anti-proliferative capabilities to disruption of the bone marrow (BM) microenvironment preventing multiple myeloma cellular development (15).